SKIN.SW Cassiopea (SIX) up 9.85% intraday 04 Feb 2026: track volume for trend

SKIN.SW stock jumped 9.85% on 04 Feb 2026, trading at CHF35.70 intraday as volume picked up to 2,756 shares and the price hit a day high of CHF36.00. This move leads our high-volume movers coverage because the stock opened at CHF32.00 and closed significantly above yesterday’s CHF32.50. Traders should note the 50-day average CHF34.37 and the 200-day average CHF37.22 while we link the midday activity to clinical programme interest and short-term liquidity shifts on the SIX market in Switzerland.

Intraday: SKIN.SW stock high-volume surge

The most important intraday fact is the 9.85% gain with volume at 2,756, above the average 1,818 — a 1.52x relative volume spike that signals active trading on SIX in Switzerland.

Price moved from the open of CHF32.00 to a day high of CHF36.00. The intraday range and elevated flow suggest short-term momentum rather than a steady breakout given the 200-day average price of CHF37.22.

Volume and liquidity snapshot

Volume today is 2,756 versus an average of 1,818, indicating sharper interest from traders and block buyers. The relative volume of 1.516 confirms higher liquidity for this typically thinly traded biotech listing.

Watch the spread and order book during the close. Low free-float listings can see outsized moves on modest volumes, so confirm continuation with follow-through volume above 3,500 shares.

Fundamentals and valuation for SKIN.SW stock

Cassiopea S.p.A. (SKIN.SW) remains a clinical-stage biotechnology company listed on SIX in Switzerland and quoted in CHF. Key ratios: EPS -1.27, PE -28.13, Price/Book 25.95, and current ratio 1.98.

Negative earnings and a high PB ratio reflect limited earnings and meaningful intangible value from the dermatology pipeline. The stock’s year range is CHF25.70 to CHF53.00, placing today’s CHF35.70 in the middle of that band.

Clinical news and catalysts driving SKIN.SW trading

Cassiopea’s pipeline — including Winlevi, Breezula, CB-06-01 and CB-06-02 — anchors the company’s news sensitivity. Intraday volume spikes often follow programme updates or investor commentary on trial enrollment and regulatory timing.

For company details and recent releases see the Cassiopea investor site source and the investor news page source. Positive clinical readouts or licensing talk could trigger further high-volume moves.

Meyka AI grades and technical outlook

Meyka AI rates SKIN.SW with a score out of 100: 58.59 | Grade: C+ | Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus.

Meyka AI’s forecast model projects a 12-month target of CHF42.50, implying an upside of 19.05% from the current CHF35.70. Forecasts are model-based projections and not guarantees. Technically, short-term resistance sits near today’s high CHF36.00 and a stronger zone at the 200-day average CHF37.22.

Risks and trade considerations

One clear risk: negative earnings and limited liquidity can amplify volatility. Key metrics include ROE -127.27% and enterprise value quirks from small-cap reporting. Earnings announcements are not scheduled, increasing event risk.

For active traders, set tight execution rules and monitor sector trends: Healthcare in Switzerland shows a 1-month performance up 3.63% for the sector, which can create tailwinds or headwinds for SKIN.SW stock.

Final Thoughts

Key takeaways: SKIN.SW stock rose 9.85% intraday to CHF35.70 on 04 Feb 2026 with volume 2,756, a clear high-volume mover on SIX in Switzerland. The move reflects short-term interest in Cassiopea’s dermatology pipeline and retains exposure to clinical and regulatory headlines. Fundamentals remain mixed: EPS -1.27, PE -28.13, PB 25.95 and a current ratio of 1.98. Meyka AI’s forecast model projects a 12-month target of CHF42.50, implying +19.05% upside from today’s price; forecasts are model-based projections and not guarantees. Traders should combine volume confirmation with catalyst calendars and respect downside thresholds near CHF32.00 and the yearly low CHF25.70. This report uses Meyka AI as an AI-powered market analysis platform to frame liquidity, valuation and clinical risk for intraday decision-making.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.